AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21543545 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative reinforcing value of food (RRV(food))
Number of subjects: 273
Study 21543545 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative proportion of responding for food compared with reading (RRV(prop))
Number of subjects: 273
Study 21544866 — intervention group
Group type: EXPERIMENTAL
Intervention: hPTH(1-34) infusion at 2 pmol/kg/h
Number of subjects: 0
Study 21544866 — intervention group
Group type: EXPERIMENTAL
Intervention: hPTHrP(1-36) infusion at 4 pmol/kg/h
Number of subjects: 0
Study 21544866 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of PTH and PTHrP infusion
Number of subjects: 0
Study 21545483 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 54
Study 21546328 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal SBP dipping (defined as ≥ 10% difference in nocturnal systolic blood pressure relative to daytime values)
Number of subjects: 663
Study 21546328 — intervention group
Group type: COMPARATOR
Intervention: Nocturnal non-dipping pattern (defined as <10% nocturnal decrease in SBP)
Number of subjects: 663
Study 21546499 — intervention group
Group type: EXPERIMENTAL
Intervention: R-ACVBP (rituximab, doxorubicine, cyclophosphamide, vindesine, bleomycine, prednisolone) followed by auto-transplantation
Number of subjects: 209
Study 21546499 — intervention group
Group type: EXPERIMENTAL
Intervention: R-ACVBP
Number of subjects: 209
Study 21546499 — intervention group
Group type: COMPARATOR
Intervention: ACVBP (without rituximab)
Number of subjects: 209
Study 21548959 — intervention group
Group type: EXPERIMENTAL
Intervention: LA-Cr formula (l-arabinose and chromium) after a 70-gram sucrose challenge
Number of subjects: 20
Study 21548959 — intervention group
Group type: COMPARATOR
Intervention: Control (70 grams of sucrose in water)
Number of subjects: 20
Study 21548986 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) regimen
Number of subjects: 0
Study 21548986 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV) regimen
Number of subjects: 0
Study 21549867 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal visceral adipose tissue (VAT)
Number of subjects: 1081
Study 21549867 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal subcutaneous adipose tissue (SAT)
Number of subjects: 1081
Study 21549867 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean body mass (LBM)
Number of subjects: 1081
Study 21549867 — intervention group
Group type: EXPERIMENTAL
Intervention: Race (African American)
Number of subjects: 1081
Study 21549867 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex (Male)
Number of subjects: 1081
Study 21550951 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin, 100 mg daily
Number of subjects: 108
Study 21550951 — intervention group
Group type: COMPARATOR
Intervention: Thiazolidinediones (rosiglitazone, 8 mg daily or pioglitazone, 45 mg daily)
Number of subjects: 108
Study 21551228 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 50 mg daily for 28 days as induction therapy and 10 mg daily for 21 days of a 28-day cycle as maintenance until disease progression or unacceptable toxicity.
Number of subjects: 37
Study 21551511 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFα inhibitor therapy
Number of subjects: 60
Study 21553174 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic surgery through single-port incision
Number of subjects: 0
Study 21553933 — intervention group
Group type: EXPERIMENTAL
Intervention: IgPro20 (subcutaneous administration, 20% solution, initial doses equivalent to 130% of previous IgPro10 doses, adjusted for AUC)
Number of subjects: 18
Study 21553933 — intervention group
Group type: COMPARATOR
Intervention: IgPro10 (intravenous administration, 10% solution)
Number of subjects: 18
Study 21553933 — intervention group
Group type: EXPERIMENTAL
Intervention: IgPro20
Number of subjects: 18
Study 21554915 — intervention group
Group type: EXPERIMENTAL
Intervention: A/turkey/Turkey/1/2005 (H5N1) vaccine (3.75 μg HA) with AS03(A)
Number of subjects: 469
Study 21554915 — intervention group
Group type: COMPARATOR
Intervention: A/turkey/Turkey/1/2005 (H5N1) vaccine (3.75 μg HA) without AS03(A)
Number of subjects: 469
Study 21554915 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccines (adjuvanted or unadjuvanted)
Number of subjects: 469
Study 21555600 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger grafts (diameter > 8.0 to 9.0 mm)
Number of subjects: 567
Study 21555600 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafts 7.0 mm to smaller than 8.0 mm in diameter
Number of subjects: 567
Study 21555600 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafts 8.0 mm in diameter
Number of subjects: 567
Study 21555600 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafts from female donors
Number of subjects: 567
Study 21555600 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafts from male donors
Number of subjects: 567
Study 21555600 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger donor age
Number of subjects: 567
Study 21555600 — intervention group
Group type: EXPERIMENTAL
Intervention: Female donor
Number of subjects: 567
Study 21555600 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger graft size
Number of subjects: 567
Study 21555610 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab, injected monthly for 6 months
Number of subjects: 17
Study 21555712 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetraethylammonium chloride (TEA)
Number of subjects: 174
Study 21555712 — intervention group
Group type: EXPERIMENTAL
Intervention: N(G)-monomethyl-l-arginine (L-NMMA)
Number of subjects: 174
Study 21555712 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 174
Study 21555712 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin
Number of subjects: 174
Study 21555712 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Number of subjects: 174
Study 21555744 — intervention group
Group type: COMPARATOR
Intervention: N9-GP (single IV dose at 25, 50, or 100 U/kg)
Number of subjects: 16
Study 21555744 — intervention group
Group type: COMPARATOR
Intervention: Previous FIX product (single IV dose at the same dose level)
Number of subjects: 16
Study 21556142 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01(E) with a 0,1,7-month schedule
Number of subjects: 0
Study 21556142 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01(E) with a 0,1- or 0,1,2-month schedule
Number of subjects: 0
Study 21556142 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02(D) with a 0,1,7-month schedule
Number of subjects: 0
Study 21556142 — intervention group
Group type: COMPARATOR
Intervention: Control Rabies vaccine using the 0,1,2-month schedule
Number of subjects: 0
Study 21556950 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin B12 (1500 μg mecobalamin daily for 3 months)
Number of subjects: 30
Study 21556950 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular vitamin B12 (1000 μg cyanocobalamin weekly for 5 weeks, then monthly for a total of 3 months)
Number of subjects: 30
Study 21557878 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose intravenous ketamine (0.2 mg/kg)
Number of subjects: 14
Study 21558357 — intervention group
Group type: EXPERIMENTAL
Intervention: β blockers with inhaled corticosteroid, long acting β agonist, and long acting antimuscarinic
Number of subjects: 5977
Study 21558357 — intervention group
Group type: COMPARATOR
Intervention: Control group (inhaled therapy with short acting β agonists or short acting antimuscarinics)
Number of subjects: 5977
Study 21558357 — intervention group
Group type: EXPERIMENTAL
Intervention: β blockers
Number of subjects: 5977
Study 21558401 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-CTLA4 antibody tremelimumab
Number of subjects: 19
Study 21558987 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m² IV) and Cyclophosphamide (600 mg/m² IV) followed by Paclitaxel (175 mg/m² IV or 80 mg/m² IV) combined with Sorafenib (400 mg oral twice a week) for 12 months or less
Number of subjects: 45
Study 21561823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligation of the deep inferior epigastric artery (DIEA)
Number of subjects: 26
Study 21562045 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 mg/m² once weekly (days 1, 8, 15, and 22; 35-day cycles)
Number of subjects: 70
Study 21562045 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3 mg/m² twice weekly (days 1, 4, 8, and 11; 21-day cycles)
Number of subjects: 70
Study 21562045 — intervention group
Group type: COMPARATOR
Intervention: 1.3 mg/m² twice weekly
Number of subjects: 70
Study 21562045 — intervention group
Group type: COMPARATOR
Intervention: 1.6 mg/m² once weekly
Number of subjects: 70
Study 21562341 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day low-sodium intake (51.3 mmol sodium/d)
Number of subjects: 1906
Study 21562341 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day high-sodium intake (307.8 mmol sodium/d)
Number of subjects: 1906
Study 21562341 — intervention group
Group type: EXPERIMENTAL
Intervention: Additive model for SNP rs4073291
Number of subjects: 1906
Study 21562405 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complications (grade IV complications)
Number of subjects: 1200
Study 21562405 — intervention group
Group type: EXPERIMENTAL
Intervention: Uneventful course
Number of subjects: 1200
Study 21562405 — intervention group
Group type: COMPARATOR
Intervention: All types of investigated procedures
Number of subjects: 1200
Study 21564455 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cost and low-resolution genotyping methods
Number of subjects: 421000
Study 21565903 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical antifungal therapy
Number of subjects: 397
Study 21565903 — intervention group
Group type: COMPARATOR
Intervention: Preemptive antifungal therapy
Number of subjects: 397
Study 21566065 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic-floor muscle (PFM) strengthening program for 4 months
Number of subjects: 23
Study 21566092 — intervention group
Group type: EXPERIMENTAL
Intervention: alemtuzumab at 30 mg IV 3 times weekly for up to 12 weeks after test dosing
Number of subjects: 28
Study 21566092 — intervention group
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Number of subjects: 28
Study 21566413 — intervention group
Group type: EXPERIMENTAL
Intervention: Valrubicin (800 mg, 6 weekly intravesical treatments)
Number of subjects: 90
Study 21567283 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest rubidium-82 (Rb-82) and FDG PET imaging
Number of subjects: 31
Study 21567283 — intervention group
Group type: EXPERIMENTAL
Intervention: Segments with significant RMM
Number of subjects: 31
Study 21569187 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/RTV 300/100 mg
Number of subjects: 41
Study 21569187 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/RTV 400/100 mg
Number of subjects: 41
Study 21569187 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (nonpregnant adults)
Number of subjects: 41
Study 21569313 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg daily for 8 weeks
Number of subjects: 1888
Study 21569378 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine treatment for ADHD
Number of subjects: 338
Study 21569559 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg/day prednisone
Number of subjects: 60
Study 21569596 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 29
Study 21570076 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive hyperemia (RH)-PAT ratio determined with peripheral arterial tonometry (PAT)
Number of subjects: 54
Study 21570076 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid intima media thickness (cIMT) determined by ultrasound
Number of subjects: 54
Study 21570199 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (gemcitabine, bevacizumab, and radiation therapy)
Number of subjects: 26
Study 21570199 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 26
Study 21570386 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (4000-40,000 IU/d) with calcium (1200 mg/d)
Number of subjects: 25
Study 21570508 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES)
Number of subjects: 1574
Study 21570508 — intervention group
Group type: COMPARATOR
Intervention: Endeavor zotarolimus-eluting stent (ZES)
Number of subjects: 1574
Study 21571677 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereoscopic digital photographs
Number of subjects: 96
Study 21571677 — intervention group
Group type: COMPARATOR
Intervention: Stereoscopic film photographs
Number of subjects: 96
Study 21572308 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest tertile of arm skeletal muscle
Number of subjects: 922
Study 21572308 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest tertile of leg skeletal muscle
Number of subjects: 922
Study 21572308 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of visceral adipose tissue (VAT)
Number of subjects: 922
Study 21572308 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower arm skeletal muscle
Number of subjects: 922
Study 21575194 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (50-300 mg/day) for 12 weeks
Number of subjects: 66
Study 21575194 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (50-300 mg/day) + Pregabalin (75-450 mg/day) for an additional 12 weeks
Number of subjects: 66
Study 21576440 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem 1 g once daily
Number of subjects: 0
Study 21576653 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D (Cardiac Resynchronization Therapy Defibrillator)
Number of subjects: 3253
Study 21576653 — intervention group
Group type: COMPARATOR
Intervention: Single-chamber defibrillator
Number of subjects: 3253
Study 21576653 — intervention group
Group type: COMPARATOR
Intervention: Dual-chamber defibrillator
Number of subjects: 3253
Study 21584903 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromosomal copy number alterations (CNAs)
Number of subjects: 95
Study 21584903 — intervention group
Group type: COMPARATOR
Intervention: Loss of chromosomal region 15q11.1-q26.3
Number of subjects: 95
Study 21584903 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of chromosomal region 12p13.31
Number of subjects: 95
Study 21584903 — intervention group
Group type: EXPERIMENTAL
Intervention: Support vector machine (SVM) model
Number of subjects: 95
Study 21585644 — intervention group
Group type: EXPERIMENTAL
Intervention: Count-to-ten fetal movement counting from pregnancy week 28 until delivery
Number of subjects: 1786
Study 21585644 — intervention group
Group type: EXPERIMENTAL
Intervention: Count-to-ten fetal movement counting in pregnancies with suboptimal outcomes (small-for-gestational-age baby, preterm birth, non-elective caesarean section)
Number of subjects: 1786
Study 21585644 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed limits for decreased fetal movements (DFMs)
Number of subjects: 1786
Study 21585644 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard approach to fetal movement counting
Number of subjects: 1786
Study 21586165 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ)
Number of subjects: 1211
Study 21586342 — intervention group
Group type: EXPERIMENTAL
Intervention: olmesartan/amlodipine (40/10mg)
Number of subjects: 720
Study 21586342 — intervention group
Group type: COMPARATOR
Intervention: perindopril (8 mg) plus amlodipine (10mg)
Number of subjects: 720
Study 21586746 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (HCT)
Number of subjects: 60
Study 21586916 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) treatment for 12 weeks
Number of subjects: 9
Study 21587329 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office immunoassay testing (index test)
Number of subjects: 1000
Study 21587329 — intervention group
Group type: COMPARATOR
Intervention: Liquid chromatography tandem mass spectrometry (LC/MS/MS) (reference test)
Number of subjects: 1000
Study 21590439 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosimilar epoetin alfa (HX575)
Number of subjects: 1000
Study 21590520 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol (2.5-15 mg/day)
Number of subjects: 14
Study 21592098 — intervention group
Group type: EXPERIMENTAL
Intervention: SumaRT/Nap (sumatriptan 85 mg and naproxen 500 mg)
Number of subjects: 135
Study 21592098 — intervention group
Group type: COMPARATOR
Intervention: Usual migraine medication
Number of subjects: 135
Study 21592984 — intervention group
Group type: EXPERIMENTAL
Intervention: TBEV vaccine
Number of subjects: 0
Study 21593054 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 21593354 — intervention group
Group type: EXPERIMENTAL
Intervention: FLVCR1 expression
Number of subjects: 71
Study 21593354 — intervention group
Group type: EXPERIMENTAL
Intervention: BCRP expression
Number of subjects: 71
Study 21593494 — intervention group
Group type: EXPERIMENTAL
Intervention: Late follicular phase (high estradiol) in fed state
Number of subjects: 9
Study 21593494 — intervention group
Group type: EXPERIMENTAL
Intervention: Late follicular phase (high estradiol) in fasting state
Number of subjects: 9
Study 21593494 — intervention group
Group type: COMPARATOR
Intervention: Early follicular phase (low estradiol) in fed state
Number of subjects: 9
Study 21593494 — intervention group
Group type: COMPARATOR
Intervention: Early follicular phase (low estradiol) in fasting state
Number of subjects: 9
Study 21593507 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucaloric reduced-carbohydrate (RedCHO)/higher-fat diet (43% carbohydrate, 39% fat)
Number of subjects: 69
Study 21593507 — intervention group
Group type: COMPARATOR
Intervention: Eucaloric standard diet (55% carbohydrate, 27% fat)
Number of subjects: 69
Study 21595953 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-selective arterial infusion of gemcitabine over 24 hours via subcutaneous indwelling port.
Number of subjects: 27
Study 21595953 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-selective arterial infusion of gemcitabine.
Number of subjects: 27
Study 21596084 — intervention group
Group type: EXPERIMENTAL
Intervention: VAX125 vaccine at a dose of 5 μg
Number of subjects: 120
Study 21596084 — intervention group
Group type: EXPERIMENTAL
Intervention: VAX125 vaccine at a dose of 8 μg
Number of subjects: 120
Study 21596084 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 5 and 8 μg groups
Number of subjects: 120
Study 21596321 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuated plaque (hypoechoic or mixed atheroma with ultrasound attenuation without calcification)
Number of subjects: 364
Study 21596321 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuated plaque
Number of subjects: 364
Study 21596321 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean attenuation score
Number of subjects: 364
Study 21596852 — intervention group
Group type: EXPERIMENTAL
Intervention: RVDD (lenalidomide 25 mg, bortezomib 1.3 mg/m(2), pegylated liposomal doxorubicin 30 mg/m(2), dexamethasone 20/10 mg)
Number of subjects: 72
Study 21600049 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT and carbon ion boost (24 GyE carbon ions in 8 fractions and IMRT 50 Gy at 2.0 Gy/fraction)
Number of subjects: 30
Study 21600054 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study 21600054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21604935 — intervention group
Group type: EXPERIMENTAL
Intervention: Active annual screening program of PSA screening for six rounds, four of which had accompanying digital rectal examination (DRE)
Number of subjects: 0
Study 21604935 — intervention group
Group type: COMPARATOR
Intervention: Patterns of screening occurring in the population in many academic and community settings across the USA
Number of subjects: 0
Study 21605131 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial tachycardia/atrial fibrillation (AT/AF)
Number of subjects: 537
Study 21605131 — intervention group
Group type: COMPARATOR
Intervention: No atrial tachycardia/atrial fibrillation (AT/AF)
Number of subjects: 537
Study 21605131 — intervention group
Group type: EXPERIMENTAL
Intervention: High average ventricular rate (≥110 beats per minute) during AT/AF
Number of subjects: 537
Study 21605131 — intervention group
Group type: COMPARATOR
Intervention: Normal average ventricular rate during AT/AF
Number of subjects: 537
Study 21605453 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Number of subjects: 195
Study 21605453 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning
Number of subjects: 195
Study 21605453 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic pre- and postconditioning
Number of subjects: 195
Study 21605453 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 195
Study 21606164 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit anti-thymocyte globulin
Number of subjects: 20
Study 21606164 — intervention group
Group type: COMPARATOR
Intervention: Horse anti-thymocyte globulin (historical control)
Number of subjects: 20
Study 21606224 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 142
Study 21606224 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 142
Study 21606224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 142
Study 21606224 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime
Number of subjects: 142
Study 21606224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 142
Study 21606224 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 142
Study 21606224 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 142
Study 21606412 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (XL184) 175 mg daily
Number of subjects: 37
Study 21606542 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA85A (2.5 × 10(7) plaque-forming units)
Number of subjects: 0
Study 21606542 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA85A (5 × 10(7) plaque-forming units)
Number of subjects: 0
Study 21606542 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA85A (10 × 10(7) plaque-forming units)
Number of subjects: 0
Study 21606542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0